Developing innovative solutions to debilitating diseases

AdAlta’s i-body^® drug discovery platform goes where antibodies do not, to create new options for debilitating diseases

• Using i-bodies – with antibody features at a fraction of the size
• Developing next generation protein and cell therapies – focused on fibrosis and immuno-oncology
• Lead asset AD-214 – first in class product for treating fibrotic diseases
• i-CAR-T cell therapies (reprogramming immune cells) – providing new hope for patients with solid tumours
• i-PET imaging – helping cancer patients know early if their immunotherapy is working